Trial Profile
A RANDOMIZED PHASE II DOUBLE-BLIND TRIAL OF SUNITINIB VERSUS PLACEBO IN COMBINATION WITH LANREOTIDE IN PATIENTS WITH PROGRESSIVE ADVANCED/METASTATIC MIDGUT CARCINOID TUMORS
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary) ; Lanreotide
- Indications Carcinoid tumour; Liver metastases; Neuroendocrine tumours
- Focus Therapeutic Use
- Acronyms SUNLAND
- 17 Jan 2020 Status changed from active, no longer recruiting to completed.
- 20 Dec 2019 According to European Clinical Trials Database record, this trial is completed in France.
- 30 Jan 2017 Planned End Date changed from 1 Mar 2017 to 1 Dec 2017.